Journal articleInvest New Drugs2013
The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer.
- Journal
- Invest New Drugs
- Published
- 4 May 2013
- Citations
- 6
- Type
- Article
These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try